ClinicalTrials.gg

Program

Dextromethorphan

Also written as “dextromethorphan”, “Drug Cocktail” and “AVP-923-20”.

Its studies are mostly in Neoplasm Metastasis · Multiple Sclerosis · Cough · Nasal Obstruction · Diabetes Mellitus, Type 2, led by 4 companies.

Furthest: phase 4, since Feb 25, 20138 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Otsuka40 open or runningphase 4since Feb 25, 2013Dec 13, 2007none ahead
Pfizer20 open or runningphase 4since Dec 7, 2010Dec 7, 2010none ahead
Johnson & Johnson10 open or runningphase 3since Jan 15, 2018Jan 15, 2018none ahead
Profil Institut für Stoffwechselforschung10 open or runningphase 2since Aug 28, 2013Aug 28, 2013none ahead

Also a collaborator on its studies: parexel, Boehringer Ingelheim, Novartis, perrigo-company, Procter and Gamble and Reckitt.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Dec 13, 2007First study: phase 3 study in Amyotrophic Lateral SclerosisNew to OtsukaOtsuka · NCT00573443 · 326 enrolled · United States, Argentina, Brazil
  2. Dec 7, 2010Pfizer's first study: phase 4 study in Common ColdNew to PfizerPfizer · NCT01257542 · 140 enrolled · United States
  3. Mar 23, 2011Phase 2 study in Multiple SclerosisOtsuka · NCT01324232 · 209 enrolled · United States, Argentina, Czechia and more
  4. Feb 25, 2013Phase 4 study in StrokeOtsuka · NCT01799941 · 367 enrolled · United States
  5. Aug 28, 2013Profil Institut für Stoffwechselforschung's first study: phase 2 study in Diabetes Mellitus, Type 2New to Profil Institut für StoffwechselforschungProfil Institut für Stoffwechselforschung · NCT01936025 · 34 enrolled · Germany
  6. Jul 8, 2015Phase 4 study in Pseudobulbar Affect (Involuntary Laughing and/or Crying)Otsuka · NCT02496039 · 5 enrolled · United States
  7. Jan 7, 2016Phase 4 study in CoughPfizer · NCT02651116 · 131 enrolled · United States
  8. Jan 15, 2018Johnson & Johnson's first study: phase 3 study in Nasal ObstructionNew to Johnson & JohnsonJohnson & Johnson · NCT03439436 · 140 enrolled · Russian Federation

TargetBeta

“Sigma opioid receptor agonist; Sigma opioid receptor agonist; Glutamate [NMDA] receptor subunit epsilon 1 antagonist; Glutamate [NMDA] receptor subunit epsilon 1 antagonist”ChEMBL 37, by rule

Studies

All 8 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT03439436Nasal Obstruction · Russian Federation3CompletedJohnson & JohnsonMay 2, 2018140
NCT02651116Cough · United States4TerminatedPfizerMar 19, 2020131
NCT02496039Pseudobulbar Affect (Involuntary Laughing and/or Crying) · United States4TerminatedOtsukaMay 20165
NCT01936025Diabetes Mellitus, Type 2 · Germany2CompletedProfil Institut für StoffwechselforschungApr 201434
NCT01799941Stroke · United States4CompletedOtsukaMay 2015367
NCT01324232Multiple Sclerosis · United States, Argentina, Czechia and more2CompletedOtsukaSep 26, 2013209
NCT01257542Common Cold · United States4TerminatedPfizerMar 2011140
NCT00573443Amyotrophic Lateral Sclerosis · United States, Argentina, Brazil3CompletedOtsukaJun 2009326

How it is read

Names in the registry

  • “Dextromethorphan”, 6 entries
  • “dextromethorphan”, 1 entry
  • “Drug Cocktail”, 1 entry
  • “AVP-923-20”, 1 entry
  • “Dextromethorphan Hydrobromide”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.